MedPath

TEIJIN PHARMA LIMITED

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

63

Active:2
Completed:38

Trial Phases

4 Phases

Phase 1:7
Phase 2:20
Phase 3:20
+1 more phases

Drug Approvals

10

NMPA:10

Drug Approvals

Febuxostat Tablets

Product Name
菲布力
Approval Number
国药准字HJ20180051
Approval Date
Aug 21, 2023
NMPA

Febuxostat Tablets

Product Name
菲布力
Approval Number
国药准字HJ20180050
Approval Date
Aug 21, 2023
NMPA

Tacalcitol Ointment

Product Name
萌尔夫
Approval Number
国药准字HJ20160628
Approval Date
Sep 18, 2021
NMPA

Alfacalcidol Tablets

Product Name
萌格旺
Approval Number
国药准字HJ20160261
Approval Date
May 8, 2021
NMPA

Alfacalcidol Tablets

Product Name
萌格旺
Approval Number
国药准字HJ20160262
Approval Date
May 8, 2021
NMPA

Alfacalcidol Tablets

Product Name
萌格旺
Approval Number
国药准字HJ20160263
Approval Date
May 8, 2021
NMPA

Febuxostat Tablets

Product Name
非布司他片
Approval Number
国药准字J20180084
Approval Date
Oct 31, 2018
NMPA

Febuxostat Tablets

Product Name
非布司他片
Approval Number
国药准字J20180085
Approval Date
Oct 31, 2018
NMPA

Febuxostat Tablets

Product Name
非布司他片
Approval Number
H20181258
Approval Date
Oct 23, 2018
NMPA

Febuxostat Tablets

Product Name
非布司他片
Approval Number
H20181257
Approval Date
Oct 23, 2018
NMPA

Clinical Trials

Distribution across different clinical trial phases (59 trials with phase data)• Click on a phase to view related trials

Phase 2
20 (33.9%)
Phase 3
20 (33.9%)
Not Applicable
10 (16.9%)
Phase 1
7 (11.9%)
phase_1_2
2 (3.4%)

A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)

Phase 1
Completed
Conditions
Acute Ischemic Stroke
First Posted Date
2020-10-29
Last Posted Date
2022-06-30
Lead Sponsor
Teijin Pharma Limited
Target Recruit Count
79
Registration Number
NCT04608838
Locations
🇯🇵

Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.